SCHEMBL29434832

SCHEMBL29434832

Cc1cc2c(cc1C1(c3ccc(C(=O)O)cn3)CC1)C(C)(C)CCC2(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 18/20 1.00
RXRB P28702 9/20 1.00
RXRG P48443 9/20 1.00
RARB P10826 6/20 1.00
RARG P13631 6/20 1.00
RARA P10276 5/20 1.00
PPARG P37231 2/20 1.00
MEN1 O00255 1/20 0.51
CYP26A1 O43174 1/20 0.51
ABCB11 O95342 1/20 0.51
ESR1 P03372 1/20 0.51
PGR P06401 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
CHRM1 P11229 1/20 0.51
DRD1 P21728 1/20 0.51
TBXA2R P21731 1/20 0.51
SLC6A2 P23975 1/20 0.51
ADRA1A P35348 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357483 1.00 RXRA (1.00) RXRARXRBRXRGRARBRARG
SCHEMBL301213 1.00 RXRA (1.00) RXRARXRBRXRGRARBRARG
SCHEMBL13752425 0.90 RXRA (0.82) RXRARXRBRXRGRARBRARG
SCHEMBL14816552 0.89 RXRA (0.80) RXRARXRBRXRGRARBRARG
SCHEMBL20411355 0.88 RXRA (0.78) RXRARXRBRXRGRARBRARG
SCHEMBL1073361 0.87 RXRA (0.77) RXRARXRBRXRGRARBRARG
SCHEMBL6376581 0.86 RXRA (0.76) RXRARXRBRXRGRARBRARG
SCHEMBL21549712 0.85 RXRA (0.74) RXRARXRBRXRGRARBRARG
SCHEMBL6889517 0.85 RXRA (0.73) RXRARXRBRXRGRARBRARG
SCHEMBL14816543 0.83 RXRA (0.71) RXRARXRBRXRGRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522646-A2 APOE LIPOPROTEIN SYSTEMS Kisbee Therapeutics, Inc. (US) 2025-03-19 EP disclosed
WO-2025024484-A1 COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER DUKE UNIVERSITY (US) 2025-01-30 WO disclosed
WO-2023220387-A2 APOE LIPOPROTEIN SYSTEMS KISBEE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
CN-109715637-B Glucokinase activators and methods of use thereof 百时美施贵宝公司 2022-04-05 CN disclosed